Targeting ST2 Alleviates Graft-Versus-Host Disease Mortality and Maintains Graft- Versus-Leukemia Jilu Zhang, PhD, Benjamin Ulrich, Abdulraouf Ramadan,

Slides:

Advertisements

Similar presentations

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

Advertisements

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease Shuichiro Takahashi, MD, Daigo Hashimoto,

Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease John M. Magenau,

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation

Role of Natural Killer Cells in Intravenous Immunoglobulin–Induced Graft-versus-Host Disease Inhibition in NOD/LtSz-scidIL2rg−/− (NSG) Mice Joëlle Gregoire-Gauthier,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

How to Treat MDS without Stem Cell Transplantation

Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Liver Transplantation for Hepatic Graft-Versus-Host-Disease: A United Network for Organ Sharing (UNOS) Database Study Shahrukh Hashmi, MD MPH, Timucin.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ-Dependent and Fas- Supported Apoptosis of Alloreactive CD4+ T Cells and Inhibit Graft-Versus-Host.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

Implementation of Post-Transplant Assessment Tools for Improved Accuracy of Graft- Versus-Host Disease Reporting Madhu Ragupathi, Jaskiran Kaur, Luda.

TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,

T Regulatory Cell Kinetics Are Altered in a Target Organ of Chronic GVHD, Resulting in a Low T Regulatory to T Effector Memory Cell Ratio Nataliya Prokopenko.

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.

Establishment of Xenogeneic Lung Chronic Graft-Verus-Host Disease Mice Model Hisaki Fujii, MD, PhD, Zhijuan Luo, MD, Xinghua Wang, MD, Susan Newbigging,

Volume 18, Issue 3, Pages (March 2003)

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia Saad S. Kenderian, MD, Marco Ruella, MD,

Deficiency of MyD88 Signaling in CD4 Tconvs Increases Tregs Suppression through Loss of ST2 Signaling, Reducing Acute Graft-Versus-Host Disease in Multiple.

Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease Nelson J. Chao, MD, MBA, Yevgeniya Gora Foster, MD, Krista Rowe, RN, MSN,

Preventing Primate Gvhd Using a Novel Antagonistic Anti-CD28 Antibody Plus Rapamycin: Downregulation of CD8 Proliferation Predicts Gvhd-Free Survival

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

ST2 is Associated with GVHD in Ex Vivo Graft Manipulation Strategies for Allogeneic Peripheral Blood Stem Cell Transplantation Caroline R. Cantilena,

Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hidekazu Itamura, M. D. , Takero Shindo, M. D. , Ph. D

Dichotomous Role of Interferon-γ in Allogeneic Bone Marrow Transplant

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation

Discovery of ST2 Inhibitors: From Biomarker to Potential Drug Target in Graft-Versus- Host Disease Chao-Yie Yang, PhD, Jilu Zhang, PhD, Etienne Daguindau,

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.

GVHD Prophylaxis with Post-Transplant High Dose Cyclophosphamide: Impact on Engraftment, Treatment-Related Mortality and Resource Utilization Nasheed.

A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease John A. Hansen, Samir M. Hanash, Laura Tabellini, Chris Baik, Richard L.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Rescue of the Mucocutaneous Manifestations in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa (RDEB) By Human Cord Blood Derived Unrestricted.

The Innate Immune Sensor Sting Can Augment or Ameliorate Graft-Versus-Host Disease Dependent on the Genetic Disparity between Donors and Recipients Cameron.

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Calcinuerin-Inhibitor (CI) Free Graft-Versus-Host Disease (GvHD) Prophylaxis: Its Effects on Magnesium, Renal Function, and the Cost of Care Marlee Muilenburg,

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Third Party Invariant Natural Killer T Cells Protect from Lethal Graft-Versus-Host Disease through Donor CD4+CD25+FoxP3+ Regulatory T Cells Dominik Schneidawind,

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect Shawn G Clouthier,

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease Wonyoung Kim, Juyang.

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Inhibition of c-Rel Activity Prevents Graft-Versus-Host Disease without Compromising Tumor Immunity Yusuke Shono, Andrea Z. Tuckett, Hsiou-Chi Liou,

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Lawrence Chang, David Frame, Thomas Braun, Erin Gatza, David A

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Close Monitoring of Cyclosporine A Concentration as a Means of Preventing Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Recipients Marietta.

Mary Eapen Biology of Blood and Marrow Transplantation

Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease John M. Magenau,

CD137 Expression Identifies Leukemia Specific CTL after in Vitro Priming of Cord Blood T Cells Previously Expanded By CD3/CD28 Co-Stimulation Jeyaraj.

Graft Versus Leukemia Effect Is Overestimated in Studies with High Rates of Graft Versus Host Disease Related Mortality: A Simulation Study Murtadha.

Presentation transcript:

Targeting ST2 Alleviates Graft-Versus-Host Disease Mortality and Maintains Graft- Versus-Leukemia Jilu Zhang, PhD, Benjamin Ulrich, Abdulraouf Ramadan, PhD, Hanenberg Helmut, MD, McKenzie Andrew, MD, PhD, Isao Tawara, M.D., Ph.D., Sophie Paczesny, MD, PhD Biology of Blood and Marrow Transplantation Volume 21, Issue 2, Pages S63-S64 (February 2015) DOI: 10.1016/j.bbmt.2014.11.064 Copyright © 2015 Terms and Conditions

Figure 1 Anti-ST2 mAb treatment reduces GVHD severity and mortality by increasing plasma IL-33 (A) The kinetics of plasma sST2 show increased sST2 levels in allogeneic group. Mice were treated with anti-ST2 or lgG isotype control via intraperitoneal injection on Day 1 and Day 1 post-transplantation (B) Survival, clinical GVHD score and (C) histopathologic analysis shows protection from GVHD in anti-ST2 treated group. (D) Increased plasma IL-33 in anti-ST2 treated group. (E)Anti-ST2 modutates transcript expression in MLN T cells. ∗pc<0.05∗∗p<0.01, ∗∗∗p<0.001, IgG vs Anti-ST2. Biology of Blood and Marrow Transplantation 2015 21, S63-S64DOI: (10.1016/j.bbmt.2014.11.064) Copyright © 2015 Terms and Conditions

Figure 2 Blockade of ST2 shifts the Th1/Th2 balance toward Th2 phenotype and increases CD4+ regulatory T cells. Spleen T cells were collected for intracellular staining at day l0 post-transplantation. ∗p<0.05, ∗∗p<0.01. Biology of Blood and Marrow Transplantation 2015 21, S63-S64DOI: (10.1016/j.bbmt.2014.11.064) Copyright © 2015 Terms and Conditions

Figure 3 Anti-ST2 mAb treatment preserves substantial GVL activity. (A) Survival cure. (B) GVHD score (bars) and percent of tumor relapse (lines). ∗∗p<0.01, IgG vs Anti-ST2 Biology of Blood and Marrow Transplantation 2015 21, S63-S64DOI: (10.1016/j.bbmt.2014.11.064) Copyright © 2015 Terms and Conditions